-
The U.S. Food and Drug Administration authorized on Wednesday an updated formula of the COVID-19 vaccine made by Pfizer and rival Moderna, which target today’s most common omicron strain.
-
In a Georgia city that is home to many refugees, the vaccination rate is higher than in the state, county, and surrounding communities of similar socioeconomic status.
-
The two-dose vaccine uses a protein-based technology, unlike the mRNA approach used in vaccines made by Pfizer and Moderna. CDC approval is still needed for ages 12-17.
-
Dr. Simone Gold was issued a medical license from the state department of health and has opened an online practice based in Naples.
-
Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.
-
The Biden administration is allowing the shot to be given between layers of skin — a method that only requires a fifth of the full dose — in order to increase vaccinations and slow the outbreak.
-
There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.
-
Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. The spike protein vaccine is more typical than the mRNA types being broadly used against COVID.
-
Three former employees have sued Walt Disney World, saying they were fired after refusing to wear face masks and get the COVID-19 vaccine due to religious reasons, according to a lawsuit.
-
The owner of a West Palm Beach nursing home will pay $1.75 million to settle claims that it improperly diverted doses of COVID-19 vaccine to members of its board of directors and donors.
-
Anti-vaccine advocates have repurposed a catchy, succinct, and potent slogan. Its unlikely source: the reproductive rights movement, which has been linked to the phrase for more than 50 years.
-
The Department of Health and Human Services will make 296,000 doses available in the coming weeks, and expects a total of 1.6 million doses to be available in the U.S. by the end of the year.